lasmiditan
Enable an agent to identify lasmiditan, assess the identity and condition of a material sample, and determine which handling or use decisions require additional evidence.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 17 findings · 27 questions
Molecular identity and form Recognize lasmiditan and preserve the distinction between its parent identity and supplied chemical form.
Parent identity
Anchor identifiers and aliases to the same molecular structure.
Structure and identifier agreement
Require agreement between the claimed lasmiditan identity, a structure-resolved reference, and sample evidence.
- Which verified structure and identifiers define lasmiditan for this record? definition
- Which reference standard and analytical results support identifying this sample as lasmiditan? provenance
Salt and moiety boundary
Record counterions and distinguish total material mass from lasmiditan content.
Hemisuccinate and content basis
Represent hemisuccinate through an explicit relationship to lasmiditan, retaining the measured composition and quantity basis.
- Is this material parent lasmiditan, hemisuccinate, another demonstrated form, or a formulation containing it? boundary
- What counterion ratio, water content, and assay basis are needed to calculate lasmiditan-equivalent mass? measurement
Composition and quality Assess whether a lasmiditan lot has the identity and composition required for its intended use.
Assay and reference
Interpret quantified lasmiditan content against a qualified reference.
Interpretable lasmiditan assay
Keep chromatographic purity, mass-based content, and parent-equivalent assay separate.
- Does the reported result measure chromatographic area purity, total mass fraction, or lasmiditan-equivalent content? measurement
- Which reference standard, qualification record, and analytical method support that result? provenance
Impurities and disposition
Evaluate non-lasmiditan constituents and their consequences for material release.
Lot fitness
Assess related substances, residual solvents, water, and other relevant contaminants against an applicable specification.
- Which impurities are identified or unresolved, and what are their measured amounts and reporting limits? measurement
- Does the lot meet a documented specification for the proposed use, or should it remain under assessment? action
Physical behavior and stability Connect lasmiditan material form to dissolution, thermal behavior, and preservation.
Form-dependent properties
Record physical measurements with enough conditions to make them transferable.
Phase and dissolution evidence
Bind phase, thermal events, and solubility measurements to the tested lasmiditan form.
- Which solid form was tested, and does the reported thermal event represent melting, desolvation, or decomposition? measurement
- What solubility was measured at the stated solvent composition, pH, temperature, and equilibration time? measurement
Storage and degradation
Judge whether handling history has compromised the material.
Supported storage disposition
Use form-specific stability evidence and actual exposure history to determine continued usability.
- Which stability study supports the storage conditions and retest period for this lasmiditan material? provenance
- After the recorded temperature, moisture, or light exposure, what reassessment is required before use? action
Pharmacological capability Represent lasmiditan's receptor activity and its relationship to medicinal effects.
Receptor pharmacology
Separate receptor binding from functional agonism and comparative selectivity.
Serotonin 1F activity
Capture evidence for 5-HT1F agonism with assay context and measured comparator activity.
- Which binding and functional assays establish lasmiditan activity at human 5-HT1F receptors? provenance
- How does activity compare with 5-HT1B and 5-HT1D under comparable assay conditions? measurement
Clinical evidence boundary
Link medicinal evidence without treating the substance as a complete treatment decision.
Substance-to-treatment link
Associate clinical claims with the studied formulation, exposure, population, and endpoint.
- Which formulation and clinical evidence support the claimed migraine-related effect? provenance
- Which conclusions concern lasmiditan itself, and which depend on a medicine, administration regimen, or patient population? boundary
Safety and permitted use Connect lasmiditan-specific safety evidence and legal status to the proposed activity.
Exposure and safety
Keep clinical impairment evidence distinct from occupational exposure classification.
Exposure-specific constraints
The cited FDA label identifies driving impairment, central nervous system depression, and serotonin syndrome warnings; their application must remain tied to medicinal exposure evidence. [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211280s008lbl.pdf)
- Which current medicinal warnings and interaction evidence apply to the contemplated use? action
- Which material-specific safety data sheet, GHS classification, and exposure-control evidence govern handling of this lot? provenance
Jurisdiction and authority
Determine whether a proposed acquisition, transfer, or use is supported by current authoritative records.
Dated legal applicability
Record legal classifications separately from product authorization and actual market availability.
- Which dated official records establish the controls applicable to lasmiditan and this material form in the relevant jurisdiction? provenance
- What conditions must the proposed acquisition, storage, transfer, or use satisfy? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of lasmiditan this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Lasmiditan is a small-molecule, centrally acting, selective serotonin 5-HT1F receptor agonist used for the acute treatment of migraine with or without aura in adults.
In scope
- Lasmiditan molecular identity and verified identifiers
- Relationships between the parent substance, salt forms, and active-moiety quantities
- Sample composition, purity, impurities, and analytical identity
- Physical state, measured properties, stability, and storage conditions
- Receptor activity and evidence-linked handling and use constraints
Out of scope
- Finished tablet formulations, excipients, packaging, and brand identities
- Individual migraine diagnosis and patient-specific prescribing
- Manufacturing processes and their operational control
- The serotonin receptor family as a biological system
- Clinical trial operations and population-level migraine management
Why it exists Filled
Enable an agent to identify lasmiditan, assess the identity and condition of a material sample, and determine which handling or use decisions require additional evidence.
Distinguishing features Filled
- Match the parent molecular structure to formula C19H18F3N3O2, CAS 439239-90-4, and PubChem CID 11610526; a name match alone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Lasmiditan)
- Distinguish parent lasmiditan from lasmiditan hemisuccinate by counterion identity and stoichiometry; the FDA label identifies hemisuccinate as the form used in the described tablets. [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211280s008lbl.pdf)
- Check evidence for selective serotonin 5-HT1F agonism when distinguishing lasmiditan from other migraine-active compounds; therapeutic indication alone does not establish identity. [IUPHAR/BPS](https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3928&tab=summary)
- Distinguish an isolated lasmiditan material from a formulated medicine by its complete composition and the basis on which its lasmiditan content is expressed.
What robots and AI may and may not do Filled
Must not
- Recommend it or a dose for a particular person's migraine.
- Advise someone that it is safe to drive or operate machinery after taking it.
- Supply it outside lawful pharmaceutical channels.
- Present it as a preventive treatment when it is for acute attacks.
Only with a human decision
- Any decision to start or change a patient's migraine treatment.
- Releasing or destroying a material lot.
May
- Identify lasmiditan by name, identifiers and documented properties, citing sources.
- Report approved uses, warnings and controlled status from official product information.
- Check a material lot's certificate of analysis against its specification.
Moral aspects Filled
- Migraine is disabling and often dismissed; honest information supports patients.
- Central effects such as dizziness and sedation put the patient and others at risk on the road.
Who is affected
- People with migraine
- Other road users
- Prescribers
Owners Filled
Steward
The marketing authorization holder for each medicine; the national medicines regulator oversees it.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.lasmiditan
- Wikidata: Q6493750 (https://www.wikidata.org/wiki/Q6493750)
Direct properties required Filled
- Parent molecular identity: Structure identifier; C19H18F3N3O2; CAS 439239-90-4; PubChem CID 11610526
- Material form: Parent substance, specified salt, hydrate or solvate if demonstrated, mixture, or unresolved
- Counterion relationship: Counterion identity and molar ratio to lasmiditan
- Lasmiditan assay: % w/w or mg/g; specify as-is, dry, salt, or parent-equivalent basis
- Impurity profile: Individual and total impurities in % or ppm, with method and reporting limits
- Solid form and thermal behavior: Observed phase; crystalline-form evidence; melting or decomposition event in °C with method
- Solubility: mg/mL or mol/L with solvent, pH, temperature, and material form
- Receptor activity: 5-HT1F binding affinity and functional potency in nM, with assay system and comparator receptors
- Stability disposition: Within supported retest period, excursion under assessment, degraded, or unknown
- Regulatory and hazard applicability: Jurisdiction, effective date, material form, intended use, applicable classification, and evidence
Recognition required Filled
- Identity rests on the label, batch record and certificate of analysis, not appearance.
- Product packs state it is for acute migraine treatment.
Capabilities and actions required Filled
- Resolve a named or labelled material to lasmiditan using structural and analytical evidence.
- Calculate parent-equivalent content from a verified salt composition and assay basis.
- Compare a lot against documented identity, purity, and stability requirements.
- Select evidence-supported dissolution, sampling, and storage conditions for the identified material form.
- Link receptor-activity evidence and medicinal safety constraints to a proposed use without generating patient-specific treatment instructions.
- Flag unresolved identity, quality, or jurisdictional constraints before releasing material for an intended use.
Hazards and failure modes required Filled
- Dizziness and sedation that can impair driving.
- Overuse of acute migraine medicines can worsen headaches.
- Misuse potential has led to controlled status in some countries.
Standards and interfaces required Filled
- ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation.
Context of use required Filled
- This compound is encountered as an active pharmaceutical ingredient for the acute treatment of migraine in adults.
- It is also used in pharmaceutical analysis and research on serotonin receptor activity, metabolism and medicine quality.
Sources Filled
- Wikidata item Q6493750: lasmiditan - identity and sense of the item
- Wikipedia: Lasmiditan - general description of the item
Open questions
- Does the wider Vercy catalogue already contain an authoritative model covering lasmiditan, and how should hemisuccinate be linked without duplicating the parent concept?
- Which validated specifications and impurity reference standards apply to the intended lasmiditan grade?
- What measured solid-form, solubility, melting or decomposition, and stability data are available separately for the parent substance and hemisuccinate?
- Which EC identifiers, material-specific GHS classifications, and occupational exposure limits are authoritatively established, and which remain unavailable?
- What are the current jurisdiction-specific controls, medicine authorizations, and availability, and which primary studies best establish receptor selectivity and its clinical interpretation?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q6493750/spec.json